15 completed, 3 unknown, 2 suspended, 2 withdrawn. 9 Phase 4, 6 Phase 3, 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 6, Unknown 2, Suspended 1 |
| Phase 3 | 6 | Completed 5, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Suspended 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
Follow Sinovac Research and Development Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Sinovac PCV13, PREVNAR 13 - Pneumococcal Infectious Disease | Phase 1 | Completed | Sinovac Research and Development Co., Ltd. | 140 | 2024-01-04 | 2026-01-28 |
| Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above Medium-dosage COVID-19 Vaccine,Inactivated, High-dosage COVID-19 Vaccine,Inactivated, Placebo-comparator group - COVID-19 | Phase 3 | Withdrawn | Sinovac Research and Development Co., Ltd. | 2023-02-20 | 2023-02-08 | |
| Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19 Experimental vaccine 1, Experimental vaccine 2, Experimental vaccine 3 - COVID-19 | Phase 4 | Suspended | Sinovac Research and Development Co., Ltd. | 480 | 2022-12-20 | 2022-08-11 |
| Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated, High-dose COVID-19 Vaccine(Vero Cell),Inactivated - COVID-19 | Phase 2 | Suspended | Sinovac Research and Development Co., Ltd. | 640 | 2022-12-15 | 2022-08-11 |
| Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose COVID-19 Vaccine (Vero Cell), Inactivated - COVID-19 | Unknown | Sinovac Research and Development Co., Ltd. | 14000 | 2022-07-30 | 2023-01-12 | |
| Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant), COVID-19 Vaccine (Vero cell), Inactivated (CZ strain) - COVID-19 | Phase 3 | Completed | Sinovac Research and Development Co., Ltd. | 1750 | 2022-06-01 | 2024-05-31 |
| Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose), COVID-19 Vaccine (Vero Cell), Inactivated (High-dose) - COVID-19 | Phase 2 | Withdrawn | Sinovac Research and Development Co., Ltd. | 2022-02-10 | 2023-09-22 | |
| Immunogenicity of an Inactivated COVID-19 Vaccine Inactivated COVID-19 Vaccine - COVID-19 | Phase 4 | Completed | Sinovac Research and Development Co., Ltd. | 395 | 2022-01-08 | 2023-09-25 |
| Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years COVID-19 Vaccine,Inactivated - COVID-19 | Phase 3 | Completed | Sinovac Research and Development Co., Ltd. | 1000 | 2021-11-27 | 2023-10-16 |
| Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell) Experimental Group, Control Group - COVID-19 | Phase 4 | Completed | Sinovac Research and Development Co., Ltd. | 520 | 2021-11-05 | 2023-10-10 |
| Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents Inactivated COVID-19 Vaccine, Controlled vaccine - COVID-19 | Phase 3 | Completed | Sinovac Research and Development Co., Ltd. | 11349 | 2021-09-10 | 2023-10-16 |
| Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic Inactivated COVID-19 Vaccine - COVID-19 | Completed | Sinovac Research and Development Co., Ltd. | 1400 | 2021-08-17 | 2022-08-23 | |
| Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2 - COVID-19 | Phase 4 | Unknown | Sinovac Research and Development Co., Ltd. | 2520 | 2021-07-27 | 2023-11-07 |
| Immunogenicity and Safety of an Inactivated COVID-19 Vaccine Inactivated COVID-19 Vaccine, 23-valent pneumococcal polysaccharide vaccine, Inactivated Hepatitis A Vaccine - COVID-19 | Phase 4 | Completed | Sinovac Research and Development Co., Ltd. | 270 | 2021-07-09 | 2022-04-14 |
| Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults SARS-CoV-2 Inactivated Vaccine, The SARS-CoV-2 Inactivated Vaccine - COVID-19 | Phase 4 | Unknown | Sinovac Research and Development Co., Ltd. | 1400 | 2021-06-19 | 2021-09-24 |
| Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults Experimental Group - COVID-19 | Phase 4 | Completed | Sinovac Research and Development Co., Ltd. | 131650 | 2021-06-05 | 2023-09-25 |
| Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults Inactivated SARS-CoV-2 Vaccine (Vero cell） - COVID-19 | Phase 4 | Completed | Sinovac Research and Development Co., Ltd. | 1080 | 2021-05-11 | 2022-04-13 |
| Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28., Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14. - COVID-19, Influenza | Phase 4 | Completed | Sinovac Research and Development Co., Ltd. | 480 | 2021-03-23 | 2021-07-26 |
| Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19 Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Two doses of placebo at the schedule of day 0,28 - COVID-19 | Phase 1 / Phase 2 | Completed | Sinovac Research and Development Co., Ltd. | 552 | 2020-10-31 | 2023-10-02 |
| Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14, Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14, Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly - Covid19 | Phase 3 | Completed | Sinovac Research and Development Co., Ltd. | 1040 | 2020-10-31 | 2021-07-27 |
Showing 20 of 22. Sign in to see all of them.
COVID-19 (20) · Influenza, Human (1) · Mumps (1) · Pneumococcal Infections (1)
sinovac COVID-19 vaccine (13) · COVID-19 Vaccines (4) · SARS-CoV-2 inactivated vaccines (2) · 13-valent pneumococcal vaccine (1) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Aging (1) · Aluminum Hydroxide (1) · Control Groups (1)
China (17) · Brazil (1) · Chile (1) · Dominican Republic (1) · Malaysia (1) · Philippines (1) · South Africa (1) · Turkey (Türkiye) (1)
Hongxing Pan, Master (4) · Dongjuan Zhang (1) · Eddy Perez-Then, Doctor (1) · Fengcai Zhu, Doctor (1) · Fubing Wang (1) · Huakun Lv, Master (1) · Javed Khan, Master (1) · Jiang Wu, Master (1) · Jingchen Ma (1) · Li Zhang, Master (1) · Qing Wang (1) · Qing Xu (1)
PMID 33217362, PMID 34197764, PMID 34890537, PMID 35660738, PMID 36383021, PMID 36441137, PMID 36658045, PMID 37325662, PMID 38812507, PMID 39107270, PMID 39313857